Merck KGaA is in advanced talks to acquire SpringWorks Therapeutics, aiming to expand its cancer treatment pipeline. While no binding agreement exists yet, a potential deal is seen as strategically ...

German healthcare giant Merck KGaA is in advanced talks to acquire U.S.-based Springworks Therapeutics, known for cancer and rare disease treatments. The potential acquisition would enhance Merck's ...

As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...

Kineta has found a new home for deals with Genentech and Merck & Co. Tidying up the portfolio ahead of its merger with TuHURA ...

We recently published a list of 12 Best Dow Stocks to Buy Right Now. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other best dow stocks to buy ...

Merck KGaA (MKGAY) confirms “advanced discussions” with Springworks Therapeutics (SWTX) regarding a potential acquisition. “Merck also confirms ...

Investors hammered Merck stock Tuesday after the company beat fourth-quarter expectations, but delivered a light 2025 outlook.

Merck's move for Sigma-Aldrich is the latest in a series of major merger and acquisition moves in the pharma sector, but creates a new company to serve the global pharma industry, rather than a ...

After a slow 2024, dealmaking in the U.S. healthcare sector is picking up. Springworks has a market value of $3 billion.

Now that the year is underway and a new presidential administration is in place in Washington, let’s consider the environment ...

President-elect Trump's return to the White House could bring an uptick in mergers and acquisitions, as markets anticipate tax and regulatory reforms that will boost dealmaking. Royal Palm ...

Merck & Co Inc on Thursday reported steady top-line growth, though profit took a hit due to the cost of recent acquis ... Subscribe now to see this Premium News article from Alliance News ...